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Alcohol is the most commonly used and abused substance worldwide. The emergence 
of alcohol use disorders, and alcohol dependence in particular, is accompanied by func-
tional changes in brain reward and stress systems, which contribute to escalated alcohol 
drinking and seeking. Corticotropin-releasing factor (CRF) systems have been critically 
implied in the transition toward problematic alcohol drinking and alcohol dependence. 
This review will discuss how dysregulation of CRF function contributes to the vulnerability 
for escalated alcohol drinking and other consequences of alcohol consumption, based 
on preclinical evidence. CRF signaling, mostly via CRF1 receptors, seems to be partic-
ularly important in conditions of excessive alcohol taking and seeking, including during 
early and protracted withdrawal, relapse, as well as during withdrawal-induced anxiety 
and escalated aggression promoted by alcohol. Modulation of CRF1 function seems to 
exert a less prominent role over low to moderate alcohol intake, or to species-typical 
behaviors. While CRF mechanisms in the hypothalamic–pituitary–adrenal axis have 
some contribution to the neurobiology of alcohol abuse and dependence, a pivotal role 
for extra-hypothalamic CRF pathways, particularly in the extended amygdala, is well 
characterized. More recent studies further suggest a direct modulation of brain reward 
function by CRF signaling in the ventral tegmental area, nucleus accumbens, and the 
prefrontal cortex, among other structures. This review will further discuss a putative role 
for other components of the CRF system that contribute for the overall balance of CRF 
function in reward and stress pathways, including CRF2 receptors, CRF-binding protein, 
and urocortins, a family of CRF-related peptides.
Keywords: alcohol, addiction, alcohol self-administration, neuropeptides, animal models, mesocorticolimbic 
system, sensitization, alcohol-related aggression
OveRview
For a few decades now, a critical role for stress in the induction, maintenance, and relapse to drug 
and alcohol dependence has been increasingly investigated. Indeed, drug dependence has been 
hypothesized as a “stress surfeit disorder” (1). Dysregulation of brain stress systems would contribute 
to the transition from drug-taking, which is primarily motivated by reward-seeking, toward esca-
lated drug-taking that becomes mainly instigated by dysphoria and negative reinforcement. As the 
very primary player mediating brain stress responses, the corticotropin-releasing factor [CRF; also 
known as corticotropin-releasing hormone (CRH)] has received great attention in drug dependence. 
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This review will discuss evidence provided by preclinical studies 
focusing on the critical participation of CRF and its closely related 
peptides urocortins, in escalated alcohol drinking, and other 
important alcohol-related behaviors. Also, apart from its role 
in more traditional brain stress circuits, this review will discuss 
increasing evidence for the CRF system as a direct modulator of 
brain reward pathways, suggesting that CRF/urocortin signaling 
may also modulate alcohol’s effects at earlier stages of alcohol 
dependence. The impact of alcohol exposure on CRF/urocortin 
signaling and plasticity will be discussed, as potential neuroadap-
tive mechanisms recruited during the establishment of alcohol 
dependence. Pharmacological manipulations targeting CRF 
receptors are presented as promising tools for reducing excessive 
alcohol drinking, withdrawal-related anxiety as well as alcohol-
induced aggression and behavioral sensitization induced by 
alcohol. The participation of the hypothalamic–pituitary–adrenal 
(HPA) stress axis is addressed at specific points, but specifically as 
a downstream target engaged by brain CRF [for reviews on HPA 
axis and alcohol, refer to Stephens and Wand (2) and Edwards 
et  al. (3)]. Finally, considerations are made on a few human 
alcohol studies evaluating polymorphisms in CRF-related genes. 
This review does not attempt to discuss alcohol studies using 
genetically modified animals for CRF-related genes, a subject 
vastly covered by a recent review on CRF systems and alcohol (4).
We refer to several review articles published on CRF and drug/
alcohol dependence [e.g., Ref. (5–7)] as well as a recent review 
specifically focusing on CRF mechanisms involved in alcohol use 
disorders (AUDs) and alcohol-induced neuroplasticity (4).
ALCOHOL AND ALCOHOL USe 
DiSORDeRS
Alcohol is the most widely consumed psychotropic substance 
worldwide. Likewise, the harmful use of alcohol ranks within 
the five main risk factors for disease, disability, and death in the 
globe (8). AUDs are responsible for ~6% of all deaths throughout 
the world, even considering potential beneficial effects of low-
risk alcohol drinking (8). Consequences of alcohol misuse can 
be both acute (e.g., acute intoxication, heavy episodic drinking, 
driving under the influence of alcohol, alcohol-related violence) 
and chronic (e.g., AUDs, gastrointestinal diseases including 
liver cirrhosis, cancers), and cause harm to the drinker, to other 
individuals, and to society in general. Thus, alcohol consumption 
is responsible for a large burden in public health, with serious 
economic and social impact.
Alcohol-related health harm is proportional to the amount of 
alcohol consumed, with a dose–response relationship. About 13% 
of the alcohol-drinking population will show a pattern of heavy 
episodic drinking, or “binge” drinking, which is more commonly 
associated with alcohol-related injury, including driving accidents 
and violent behavior (9). AUDs are the main neuropsychiatric 
condition promoted by alcohol consumption and encompass 
both the harmful use of alcohol and alcohol dependence. Alcohol 
dependence affects ~5% of the adult (15 years and older) popula-
tion worldwide (8) and consists of a variety of behavioral, cogni-
tive, and physiological symptoms that follow repeated alcohol 
use. According to the International Classification of Diseases, 
main features of alcohol dependence include a strong desire to 
consume alcohol; difficulties in controlling the frequency and 
amount of alcohol consumption; persistent use despite perceived 
harmful consequences; a higher priority given to obtaining and 
using alcohol relative to other activities and obligations; increased 
tolerance; and sometimes a physiological withdrawal state (10).
Despite the complexity of biological, environmental, and 
social factors that influence drug and AUDs, animal models have 
been instrumental in providing evidence for behavioral, phar-
macological, and neurobiological mechanisms underlying acute 
and repeated alcohol exposure [for a review, see Ref. (11)]. This 
review will focus primarily on findings stemming from preclini-
cal studies and how they contribute to our understanding of CRF/ 
urocortin mechanisms in alcohol dependence. Of particular 
interest are models of voluntary alcohol consumption, including 
home cage drinking (e.g., two-bottle choice, with intermittent, 
limited, or continuous access conditions; the “drinking in the dark” 
model, etc.) and operant self-administration (animals respond 
by pressing a lever or nose poking in order to obtain an alcohol 
reward). Using these experimental models, it is also possible to 
promote escalated, excessive alcohol intake by using protocols of 
repeated and prolonged voluntary access to the substance, usu-
ally followed by one or multiple cycles of withdrawal. Examples 
are procedures such as the alcohol-deprivation effect (12) and 
dependent-like alcohol consumption in subsets of chronically 
drinking rats and mice [e.g., Ref. (13, 14)]. Other widely used 
procedures for escalated drinking rely on forced alcohol exposure 
in order to obtain reliable and consistent exposure to high alcohol 
concentrations, such as the alcohol vapor chamber (15, 16), as 
well as alcohol-containing liquid diet [see also Ref. (17) for a 
review]. Such excessive alcohol exposure is usually associated 
with withdrawal symptoms upon short-term withdrawal, and 
dysphoria and anxiety during protracted abstinence. These nega-
tive features trigger and motivate increased levels of voluntary 
alcohol self-administration [e.g., Ref. (18); see review by Heilig 
and Koob (5)].
Different from other drugs of abuse, such as cocaine, 
amphetamines, and morphine, pharmacological mechanisms for 
alcohol include a variety of targets in the central nervous system. 
Synaptic actions of alcohol have been described with several 
neurotransmitter-gated ionotropic receptors (e.g., GABAA, 
glutamate NMDA and AMPA receptors, serotonin 5-HT3 
receptors, etc.), ion channels (e.g., different subtypes of calcium 
and potassium channels), as well as intracellular downstream 
signaling proteins also involved in metabotropic receptors 
cascades (e.g., diacylglycerol, protein kinase A, protein kinase 
C, etc.), as extensively reviewed by Lovinger and Roberto (19). 
Additionally, presynaptic effects of alcohol may be observed, with 
a facilitation or potentiation of presynaptic GABA release, but 
not glutamate, as revealed by electrophysiological studies using 
slice preparations or isolated neurons [reviewed by Lovinger and 
Roberto (19) and Siggins et al. (20)]. Chronic alcohol exposure 
produces consistent neuroadaptive changes in the function 
of both ionotropic and metabotropic glutamate receptors, for 
example, with the upregulation of NMDA receptors [e.g., Ref. 
(21–25)]. Likewise, GABAA receptors are markedly affected in 
their subunit composition, sensitivity, and function by chronic 
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alcohol treatment [see reviews by Grobin et al. (26) and Kumar 
et al. (27)]. These and many other changes in synaptic function, 
which vary in different brain regions, are considered critical for 
the development of tolerance and dependence to alcohol (19).
The effects of alcohol are importantly modulated by neuro-
peptides, including opioid peptides, neuropeptide Y, orphanin/
nociceptin, and orexin. This review will focus on the family of 
neuropeptides comprised of CRF and its closely related peptides, 
the urocortins. The next section will briefly describe the physiol-
ogy of CRF/urocortin signaling in the brain, and subsequently we 
will discuss the critical role of CRF signaling in AUDs.
A GLANCe AT CRF/UROCORTiN 
SYSTeMS iN THe BRAiN
The 41-amino acid neuropeptide CRF was identified in 1981 by 
Vale and colleagues and has long been associated with neural, 
endocrine, autonomic, and immune responses to stress (28). 
Acting as a neuromodulator, the availability of CRF is critically 
determined by the CRF-binding protein (CRF-BP), a glycoprotein 
that regulates the extracellular availability of CRF to bind to its 
receptors (29, 30). CRF exerts its effects via interaction with two 
G-protein coupled receptors, namely CRFR1 and CRFR2 (CRF 
receptor 1 and 2, respectively), which are found in several vari-
ants (31). However, CRF has a 10-fold higher affinity for CRFR1 
relative to CRFR2 (32). Urocortins, another set of peptides in the 
CRF family, are the main endogenous ligands for CRFR2, show-
ing similar affinity for both receptor subtypes (urocortin 1), or 
binding almost exclusively to CRFR2 [urocortins 2 and 3; (33)]. 
Activation of both CRFR1 and CRFR2 preferentially lead to the 
activation of cyclic-AMP second messenger pathways (34). The 
two receptor subtypes are differentially distributed in the brain, 
with overlapping regions (35). CRFR1 are more ubiquitously 
found. In rodents, high densities of CRFR1 are found in the 
anterior hypophysis, cerebral cortex, cerebellum, amygdala, hip-
pocampus, and striatum (36), whereas CRFR2 are more limited 
to the mesencephalon, raphé nuclei, lateral septum, amygdala, 
and hypothalamus (37), as recently reviewed by Phillips et al. (4). 
Although not the focus of the current review, CRF and urocortin 
peptides, as well as receptors and binding protein, are widely 
distributed in peripheric organs and tissues, including the gas-
trointestinal tract, cardiovascular, and immune systems, where 
they integrate systemic stress responses and participate in other 
functions [see reviews by Fekete and Zorrilla (33), Pan and Kastin 
(38), Stengel and Taché (39)].
As a major modulator of systemic neuroendocrine stress 
responses, hypothalamic CRF drives the HPA axis, with second-
ary modulation by the neuropeptide arginine vasopressin [e.g., 
Ref. (28, 40, 41)]. Produced by parvocellular and magnocellular 
neurons of the paraventricular nucleus of the hypothalamus 
(PVN), AVP has a limited capacity to activate the HPA axis by 
itself (4, 42). However, the neuropeptide AVP seems to increase 
the effects of CRF on HPA axis by synergistic activation of its 
V1b receptor in the anterior pituitary (4, 42, 43). Produced 
by parvocellular neurons of the PVN, CRF is released in the 
median eminence to reach the anterior hypophysis (or pituitary), 
where it binds to densely expressed receptors, CRFR1 (44). 
Adrenocorticotropic hormone (ACTH) is then secreted into 
the blood stream by the adenohypophysis (45). Once secreted, 
ACTH stimulates the production and release of glucocorticoids 
from the cortex of adrenal glands (cortisol in humans, corticos-
terone in rodents). Glucocorticoids will then act upon high- and 
low-affinity receptors (mineralocorticoid and glucocorticoid 
receptors, respectively), widely distributed in the periphery 
and the brain. Cortisol and corticosterone promote adaptive 
responses to environmental challenges and stressors, including 
changes in energy metabolism, physiological, and behavioral 
responses. HPA axis function is importantly regulated via inhibi-
tory feedback by glucocorticoids, ultimately reducing activity of 
PVN neurons and CRF release. For a more complete discussion 
on HPA axis signaling and functions, we refer to reviews by 
Herman et al. (45), McEwen (46), Myers et al. (47), Sapolsky et al. 
(48), and Ulrich-Lai and Herman (49).
Wide distribution of cell bodies and fibers with immunore-
activity for CRF is found in stress-related pathways involving 
amygdalar nuclei [especially the central nucleus of the amygdala 
(CeA)], the bed nucleus of the stria terminalis (BNST), and the 
PVN, with ascending projections to forebrain structures as well 
as descending innervations to the brain stem (31). High levels 
of CRF are also detected in the hippocampus, thalamus, locus 
coeruleus, raphé nuclei, and other mesencephalic structures 
(50, 51). Detection of neurons and fibers containing urocortin 
peptides are limited to fewer brain structures and projection 
sites in rodents, although a wider distribution of brain urocortin 
can be found in human and non-human primates (38, 52, 53). 
As extensively reviewed by Fekete and Zorrilla (33), urocortin 
1 (Ucn1) is primarily synthesized in the centrally projecting 
Edinger–Westphal nucleus, a midbrain structure, and other 
secondary sites. Descending fibers of Ucn1 are found in many 
regions, including the substantia nigra, the dorsal raphe nucleus, 
and periaqueductal gray, while ascending fibers of Ucn1 are 
found in the lateral septum, BNST, hypothalamus, and other 
structures. Urocortin 2 (Ucn2) is synthesized in the PVN and 
other hypothalamic nuclei, as well as in the locus coeruleus, but 
its projection targets are unknown (33). Urocortin 3 (Ucn3) is 
produced in hypothalamic and amygdala regions. Ucn3 fibers 
project from the amygdala to the hypothalamic ventral premam-
millary nucleus, while fibers from undertermined origins are 
also found in other hypothalamic regions, in lateral septum, 
BNST, medial amygdala, and ventral hippocampus [for reviews, 
see Ref. (33, 54)].
Briefly, biological functions mediated by CRF and urocortin 
peptides include not only stress responses but also regulation of 
appetitive responses, such as feeding and exploratory behaviors, 
and a variety of social behaviors (38, 55, 56). In several of these 
functions, CRF receptor subtypes often play different roles (57, 
58). For example, stress and anxiety-like responses are thought 
to be primarily initiated by CRF/urocortin 1 activation of CRFR1 
signaling, while CRFR2 activation has been associated with 
anxiolytic effects and/or termination of stress responses (38, 59). 
As another example, CRF and urocortins inhibit feeding behavior 
likely via CRFR2 signaling, although both CRFR1 and CRFR2 
are involved in stress-induced anorexigenic effects (54). Thus, 
biological responses involving CRF and urocortins are wide and 
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complex, and recruitment of specific CRF receptors will vary 
according to each particular behavior and/or pathology, in a 
brain region-dependent manner.
Through actions on CRFR1 and/or CRFR2, CRF and urocor-
tin peptides set the pace for brain monoaminergic function in 
regions, such as the locus coeruleus (primary site for noradrener-
gic neurons in the brain), the dorsal and median raphé (serotonin 
neurons), and the ventral tegmental area (VTA), where reward-
related dopamine neurons are located [e.g., Ref. (57, 60–62)]. 
Of particular interest to this review, dopamine neurons in the 
VTA receive CRF inputs from fibers that originate in the BNST, 
the CeA and, to a lesser extent, the hypothalamic PVN (63). In 
the VTA, CRF stimulates firing of dopamine neurons likely via 
CRFR1 signaling, modulating dopamine output to the nucleus 
accumbens (64). On the other hand, when CRF is directly applied 
in the nucleus accumbens, it can increase dopamine release and 
promote appetitive behavior (65). Exposure to acute stress is well 
known to induce activation of this dopamine pathway arising 
from the VTA and projecting to the nucleus accumbens and the 
prefrontal cortex, typically promoting increased drug-taking and/
or drug-seeking behaviors [see review by Holly and Miczek (66)]. 
Interestingly, the ability of stress to trigger activation of dopamine 
brain reward pathways may be a downstream event from stress-
induced increased CRF signaling within the VTA. For example, 
acute exposure to footshock stress promotes marked increases in 
CRF levels in the VTA and is associated with dopamine increases 
in the VTA and with reinstatement of cocaine-seeking behavior 
in cocaine-experienced rats (67). Remarkably, these CRF effects 
seem to be primarily mediated by CRFR2 in the VTA (68). More 
recently, acute or repeated social defeat stress were also shown 
to phasically increase CRF levels in the VTA, but with regional 
heterogeneity (anterior vs. posterior subregions of VTA), while 
repeated stress promotes long-term increases in CRF tonus in 
both subregions (69). In this case, both CRFR1 and CRFR2 mod-
ulated cocaine-seeking behaviors in rats with a history of social 
stress, according to the subregion of the VTA (69). Evidence for 
the involvement of CRF/urocortin signaling in alcohol drinking 
and other alcohol-related behaviors will be specifically addressed 
in the following sections.
MODULATiON OF ALCOHOL 
CONSUMPTiON BY PHARMACOLOGiCAL 
MANiPULATiONS OF CRF/UROCORTiN 
SiGNALiNG
Extensive evidence points to a critical role for CRF and CRFR1 
receptors in escalated alcohol consumption [(70–74); see review 
by Phillips et al. (4)]. As summarized in Table 1, antalarmin – a 
non-peptidergic CRFR1 antagonist – reduces free-choice alcohol 
drinking in rats given intermittent access to alcohol (72). Mice 
chronically exposed to alcohol vapor showed reduced escalated 
alcohol self-administration when treated with antalarmin prior 
to the withdrawal drinking session (75). In this study, control 
mice showed no changes in alcohol self-administration when 
treated with antalarmin, suggesting that only excessive drinking, 
in this case withdrawal-induced drinking, was sensitive to CRFR1 
treatment (75). Binge drinking in C57BL6 mice was attenuated by 
another CRFR1 antagonist, CP-154,526, using the drinking-in-
the-dark protocol (76). However, alcohol consumption was only 
reduced in high drinking conditions (blood alcohol ~80 mg/dl), 
not in moderate drinking conditions (blood alcohol ~40 mg/dl or 
lower). Other systemically administered CRFR1 antagonists were 
also effective in attenuating drinking-in-the-dark consumption, 
such as CP 376,395 and NBI-27914, despite non-selective effects 
reducing water and calory intake as well (77). The possibility that 
reduced alcohol drinking due to CRFR1 blockade could be sec-
ondary to broader effects on fluid and calory intake needs to be 
further investigated (77). A couple of studies failed to observe an 
attenuation of alcohol intake by CRFR1 antagonist when animals 
had continuous access to the drug [e.g., Ref. (78, 79)].
Overall, these studies suggest that systemic CRFR1 antagonists 
present selective actions in reducing escalated alcohol drinking, 
but not moderate drinking, as summarized in Table 1 [e.g., Ref. (75, 
76, 88)]. One particular study suggests that these effects are likely 
extra-hypothalamic and independent from HPA axis activation, 
since adrenalectomized mice show similar binge alcohol intake 
as controls, and CRFR1 blockade remains effective in attenuating 
drinking in adrenalectomized animals (86). Non-selective pep-
tidergic CRF receptor antagonists, such as alpha-helical CRF or 
d-Phe-CRF, usually present a similar profile of effects as those of 
selective CRFR1 antagonists. In particular, icv infusion of d-Phe-
CRF has been shown to reduce escalated alcohol drinking (106) 
and prevent reinstatement of stress-induced alcohol seeking (82, 
107), just like more selective CRFR1 antagonists (see Table 1). 
When a selective CRFR1 antagonist was given chronically via 
icv minipumps, however, reduced drinking was only observed 
on the first drinking day and not on the following test sessions, 
suggesting that the chronic, continuous blockade of CRFR1 may 
not be as effective (84).
Important brain regions for the anti-drinking effects of selec-
tive CRFR1 and non-selective CRFR1/2 antagonists include 
brain reward and stress-related regions. For example, infusion 
of CP-154,526 into the VTA attenuated binge drinking in 
C57BL/6J mice (89). A different study also showed a reduction 
in two-bottle choice drinking in both rats and mice after intra-
VTA infusion of CP-154,526 (74). CRFR1 signaling in the dorsal 
raphé nucleus (DRN) is also recruited for escalated alcohol 
drinking in rats and mice, likely due to a CRFR1 modulation 
of serotonergic output to the prefrontal cortex (74, 84). On the 
other hand, while CRFR1 in the median raphé nucleus may not 
modulate drinking (84), blockade of CRFR1/2 in this region 
prevents stress-induced reinstatement of alcohol seeking (103, 
111). Infusion of either the non-selective antagonist d-Phe-CRF 
or antalarmin into the CeA also attenuates binge drinking (73) 
and withdrawal-induced alcohol self-administration (108–110). 
Notably, the preferential, but non-selective, activation of CRFR1 
by CRF itself, whether icv or in different brain regions, produces 
inconsistent outcomes in alcohol drinking [e.g., Ref. (100, 101, 
104, 105)]. Nonetheless, infusion of CRF into the ventricles 
or into the median raphé promotes reinstatement of alcohol-
seeking behavior (103).
Using a different procedure, high alcohol-preferring P rats 
were exposed to three cycles of voluntary alcohol drinking 
TABLe 1 | Summarized effects of pharmacological manipulations of CRF/urocortin targets on alcohol-drinking studies.
Receptor Mechanism Drug Drug 
administration
Results Reference
CRFR1 Antagonist Antalarmin ip Reduced escalateda drinking Lodge and Lawrence (71), Cippitelli 
et al. (72), Hansson et al. (70), 
Chu et al. (75), Marinelli et al. (80), 
Lowery-Gionta et al. (73)
Reduced ethanol seeking Marinelli et al. (80), Funk et al. (81)
No effect on escalateda drinking Yang et al. (79), Molander et al. (78)
Into CeA Reduced escalateda drinking Lowery-Gionta et al. (73)
CRFR1 Antagonist CP-154,526 ip Reduced stress-induced reinstatement of 
ethanol seeking
Le et al. (82)
Reduced escalateda drinking Correia et al. (83), Hwa et al. (84), 
Lowery et al. (85, 86), Overstreet et al. 
(87), Sparta et al. (76, 88)
icv (chronic 
minipump)
No effect on escalateda drinking Hwa et al. (84)
Into VTA Reduced escalateda drinking Hwa et al. (74), Sparta et al. (89)
Into DRN Reduced escalateda drinking Hwa et al. (74, 84)
Into MRN No effect on escalateda drinking Hwa et al. (84)
CRFR1 Antagonist CP 376,395 ip Reduced escalateda drinking Giardino and Ryabinin (77),  
Hwa et al. (84), Simms et al. (90)
icv (chronic 
minipump)
Reduced escalateda drinking only on day 1;  
no effect in remaining days
Hwa et al. (84)
CRFR1 Antagonist CRA-1000 ip Reduced escalateda drinking Overstreet et al. (87, 91),  
Lowery-Gionta et al. (73)
CRFR1 Antagonist LWH-63 ip Reduced escalateda drinking Lowery-Gionta et al. (73)
sc Reduced escalateda drinking Sabino et al. (92)
Modestly increased limited access alcohol and 
water drinking
Sabino et al. (92)
CRFR1 Antagonist MJL-1-109-2 ip Reduced escalateda drinking Funk et al. (81)
No effect on drinking Sabino et al. (92)
CRFR1 Antagonist MPZP sc Reduced escalateda drinking Gilpin et al. (93), Richardson et al. (94)
No effect on escalateda drinking Ji et al. (95)
CRFR1 Antagonist MTIP ip Reduced stress-induced reinstatement of ethanol 
seeking
Gehlert et al. (96)
Reduced escalateda drinking Gehlert et al. (96)
CRFR1 Antagonist NBI-27914 ip Reduced escalateda drinking Lowery-Gionta et al. (73), Giardino 
and Ryabinin (77)
CRFR1 Antagonist NBI-27914 ip No effect on escalateda drinking Molander et al. (78)
CRFR1 Antagonist R121919 ip No effect on escalateda drinking Yang et al. (79)
sc Increased escalateda drinking Sabino et al. (92)
Prevented stress-induced suppression of drinking Sabino et al. (92)
No effect on escalateda drinking Sabino et al. (97)
Reduced escalateda drinking Funk et al. (81), Roberto et al. (24), 
Roltsch et al. (98)
CRFR1 Antagonist SSR125543 Into NAcc Reduced escalateda drinking Knapp et al. (99)
Into AMY, DRN No effect on escalateda drinking Knapp et al. (99)
CRFR1/2 Agonist CRF icv No effect on escalateda drinking O’Callaghan et al. (100)
Reduced escalateda drinking Bell et al. (101), Thorsell et al. (102)
Reinstated CRF-induced ethanol seeking Le et al. (103)
Into DRN No effect on drinking Weitemier and Ryabinin (104)
Into LS Reduced escalateda drinking and water intake Ryabinin et al. (105)
Into MRN Reinstated CRF-induced ethanol seeking Le et al. (103)
Into NAcc Further augmented escalateda drinking Knapp et al. (99)
CRFR1/2 Agonist CRF Into CeA, DRN, 
VTA, PVN
No effect on escalateda drinking Knapp et al. (99)
CRFR1/2 Agonist Ucn 1 Into DRN No effect on drinking and reduced water intake Weitemier and Ryabinin (104)
Into LS Reduced escalateda drinking Ryabinin et al. (105)
CRFR1/2 Antagonist d-Phe-CRF icv Reduced escalateda drinking Valdez et al. (106)
(Continued)
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Receptor Mechanism Drug Drug 
administration
Results Reference
Reduced reinstatement of ethanol seeking induced 
by the combination of stress and ethanol-cues
Liu and Weiss (107)
Reduced stress-induced reinstatement of ethanol 
seeking
Le et al. (82), Liu and Weiss (107)
No effect on cue-induced reinstatement of ethanol 
seeking
Liu and Weiss (107)
Into CeA Reduced escalateda drinking Finn et al. (108), Funk et al. (109, 110)
Into MRN Reduced yohimbine-induced reinstatement Le et al. (111)
Into MRN Reduced stress-induced reinstatement Le et al. (103)
CRFR1/2 Antagonist Alpha-helical CRF icv Increased drinking in low preference animals O’Callaghan et al. (100)
Reduced escalateda drinking Lowery et al. (86)
No effect on drinking in high preference animals O’Callaghan et al. (100)
CRFR2 Agonist Ucn 3 icv Reduced escalateda drinking Sharpe and Phillips (112), Valdez et al. 
(113), Lowery et al. (86)
Into CeA Reduced escalateda drinking Funk and Koob (114)
Increased drinking in control animals Funk and Koob (114)
CRFR2 Antagonist Astressin-2B Into VTA Reduced escalateda drinking Albrechet-Souza et al. (115)
Into CeA No effect on escalateda drinking Albrechet-Souza et al. (115)
CRFR2 Antagonist Antisauvagine-30 Into DRN No effect on drinking Weitemier and Ryabinin (104)
CRF-BP Antagonist CRF(6–33) Into VTA Reduced escalateda drinking Albrechet-Souza et al. (115)
Into CeA No effect on escalateda drinking Albrechet-Souza et al. (115)
aEscalated drinking refers to ethanol intake that is above baseline or control levels, as observed in protocols of alcohol deprivation, “binge” drinking (as in drinking-in-the-dark 
protocol), intermittent/limited access conditions, withdrawal from ethanol vapor or liquid diet exposure, prolonged ethanol access conditions, etc.
ip, intraperitoneal; sc, subcutaneous; icv, intracerebroventricular; AMY, amygdala; CeA, central nucleus of the amygdala; BLA, basolateral amygdala; DRN, dorsal raphé nucleus; 
MRN, median raphé nucleus; PVN, paraventricular nucleus of the hypothalamus; VTA, ventral tegmental area; NAcc, nucleus accumbens; LS, lateral septum.
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(5 days), with 2-day withdrawal periods in between cycles (99). 
During withdrawal periods, rats received the infusion of a CRFR1 
antagonist, SSR 125543, into the nucleus accumbens prior to 
exposure to restraint stress. Escalated drinking was promoted by 
the multiple cycles of withdrawal and stress exposure, and was 
attenuated by the blockade of CRFR1 in the accumbens dur-
ing withdrawal periods (99). Using the same protocol, CRFR1 
blockade in the DRN or the amygdala failed to affect escalated 
alcohol drinking (99). Interestingly, intra-accumbens infusion 
of CRF itself during the withdrawal periods (as a substitute for 
restraint stress) augmented alcohol consumption but had no 
effects on drinking when microinjected into the VTA, amygdala, 
DRN, or the paraventricular nucleus of the hypothalamus (99). 
Thus, plastic changes in accumbal CRFR1 seem to be recruited 
during cycles of withdrawal and stress, which underlie escalated 
drinking.
A few studies also suggest the involvement of urocortin pep-
tides and CRFR2 in the modulation of escalated alcohol drinking. 
In mice, infusion of Ucn 1 (a non-selective agonist at CRFR1/2) 
into the lateral septum, but not into the dorsal raphé, significantly 
blunts binge alcohol drinking, likely due to a preferential action 
on CRFR2 (105). The selective activation of CRFR2 with icv 
administration of Ucn 3 reduced alcohol intake in mice (86, 112) 
and rats (113). Interestingly, this attenuation of escalated alcohol 
consumption can also be observed after infusion of Ucn 3 into the 
CeA of rats withdrawn from chronic alcohol vapor (114). On the 
other hand, blockade of CRFR2 in the CeA with astressin-2B failed 
to affect binge alcohol drinking in mice (115). Thus, these studies 
suggest that it is the activation, not the blockade of CRFR2, which 
prevents or attenuates excessive alcohol drinking, icv, or in regions 
such as the lateral septum or the CeA. However, one recent study 
reported decreased alcohol intake after infusion of a selective 
CRFR2 antagonist into the VTA (115), suggesting that different 
roles for CRFR2 may emerge from different brain pathways.
In summary, both subtypes of CRF receptors seem to be 
important during escalated alcohol drinking. While consistent 
and extensive evidence weighs toward CRFR1 modulation of 
excessive alcohol intake, increasing studies are currently sug-
gesting that a balance between CRFR1 and CRFR2 activation/
blockade may be critical in determining the final outcome. In par-
ticular brain regions such as the CeA, it seems that the inhibition 
of CRFR1 signaling and/or facilitation of CRFR2 function will 
blunt excessive alcohol drinking. On the other hand, blockade 
of either CRFR1 or CRFR2 in the VTA is effective in attenuating 
drinking (74, 89, 115). Thus, both CRFR1 and CRFR2 are impor-
tant pharmacological targets that can contribute to treatment 
of AUDs. Furthermore, targets, such as the CRF-BP, have just 
started to emerge as interesting modulators of alcohol drinking, 
as recently suggested by Albrechet-Souza et al. (115).
CRF/UROCORTiN MODULATiON OF 
OTHeR ALCOHOL-ReLATeD BeHAviORS
Conditioned Place Preference
Conditioned place preference is a common model for indirectly 
assessing drug reward and drug seeking, by associating drug-
induced reinforcing effects to a particular environment [for 
7Quadros et al. CRF Mechanisms in Alcohol Use Disorders
Frontiers in Endocrinology | www.frontiersin.org October 2016 | Volume 7 | Article 134
reviews, see Ref. (116–118)]. In this model, alcohol has reliably 
produced conditioned reward as evidenced by increased time 
spent in the alcohol-paired environment, relative to a different 
saline-paired environment, when the animal is tested in the 
absence of the drug (i.e., conditioned preference).
Genetic manipulations of the CRF system seem to affect the 
conditioned reinforcing effects of alcohol. Olive et al. (119) showed 
that transgenic CRF knockout mice fail to present preference to 
the alcohol-paired environment after conditioning sessions with 
a moderate dose of alcohol (2 g/kg), in a protocol that promotes 
significant preference in wild-type controls. Nonetheless, with 
a higher conditioning dose of alcohol (3  g/kg), both wild-type 
and knockout mice presented conditioned preference for the 
alcohol-associated context (119). These results suggest that CRF 
may have a facilitatory role in alcohol-conditioned reward, but 
other mechanisms contribute as well.
Urocortin1 knockout mice failed to present preference to the 
alcohol-paired environment (2  g/kg conditioning dose), and 
this strain also presents decreased alcohol intake and preference 
in a two-bottle choice protocol (120). Nonetheless, alcohol-
conditioned aversive effects were preserved in this strain, sug-
gesting that different mechanisms underlie conditioned reward 
and conditioned aversion (120). Furthermore, CRFR2 knockout 
mice do not display alcohol-induced conditioned place prefer-
ence (120). Since Ucn1 acts on both CRFR1 and CRFR2, authors 
suggest that Ucn1-mediated activation of CRFR2 would be criti-
cal for the conditioned effects of alcohol. These were the only two 
studies assessing conditioned place preference for alcohol and 
CRF/urocortin systems. Determination of specific mechanisms 
requires assessment of the role of CRFR1 in this model, and 
further pharmacological studies.
Behavioral Sensitization
Similar to other drugs of abuse, repeated injections of alcohol 
promotes neuroadaptation in brain reward pathways, rendering 
the brain more vulnerable and sensitive to drug-induced reward 
and stimulation [see reviews by Robinson and Berridge (121, 122), 
Steketee and Kalivas (123), Vanderschuren and Pierce (124)]. 
Behaviorally, this neurochemical sensitization may be accompa-
nied by progressively augmented motor stimulation responses or 
“behavioral sensitization” [e.g., Ref. (125–129)]. Different from 
other drugs, however, alcohol-induced locomotor sensitization is 
not easily demonstrated in rats1 (130, 131) but is well described 
in some inbred and outbred strains of mice [e.g., Ref. (132–135); 
see also Ref. (136) for a report on adolescent macaques]. Also, a 
putative role for sensitized behavioral responses to alcohol has 
been suggested as a vulnerability factor for alcohol dependence 
in humans (137, 138).
Components of the CRF system play a critical role in alcohol-
induced behavioral sensitization, as also reviewed by Phillips 
et al. (4). Studies with transgenic mice show that CRF and CRFR1 
1 This affirmation refers exclusively to locomotor sensitization induced by alcohol. 
Neurochemical sensitization of the dopamine reward system and sensitization 
to other behaviors and drugs (including cross-sensitization between alcohol and 
other drugs; withdrawal-induced sensitization of anxiety-like behaviors, etc.) have 
been extensively demonstrated in rats. 
are required for alcohol sensitization (139, 140). Mice homozy-
gous for CRF gene depletion do not show a sensitized locomotor 
response to alcohol after repeated injections, while heterozygous 
animals develop normal levels of sensitization (140). CRFR1 
knockout mice failed to develop alcohol sensitization and also 
show a reduction in the acute response to alcohol (119, 139). On 
the other hand, knockout mouse lines for CRFR2 or urocortin 1 
both develop normal levels of sensitization (139), suggesting no 
particular role for CRFR2 in alcohol sensitization.
As shown in Table  2, pharmacological blockade of CRFR1 
receptors with CP-154,526 (in doses of 10 mg/kg and higher; ip) 
consistently abolishes the expression of a sensitized locomotor 
stimulation after a 10-day alcohol treatment regimen, without 
affecting the acute response to alcohol in DBA/2J mice (139, 141). 
During the induction phase, the effects of the CRFR1 antagonist 
are less clear, with significant attenuation of alcohol sensitiza-
tion only at a high 30 mg/kg dose of CP-154,526 [no effects at 
lower doses; (139, 141)]. No studies were found assessing the 
pharmacological manipulation of CRFR1 in different inbred or 
outbred lines of mice other than DBA/2J, nor were these CRFR1 
pharmacological manipulations tested in particular brain sites, as 
shown in Table 2. Future studies should broaden our understand-
ing of the critical CRF/CRFR1 mechanisms underlying alcohol 
sensitization. Furthermore, while glucocorticoids seem to play a 
role in alcohol sensitization (139, 140, 142–144), it remains to be 
determined whether glucocorticoid involvement in this process 
is directly mediated by upstream CRF signaling.
Alcohol-escalated Aggression
Moderate doses of alcohol may promote escalated levels of aggres-
sive behaviors in mice, rats, monkeys, and humans [see reviews 
from Miczek et  al. (156, 157)]. In mice, alcohol-heightened 
aggression seems to involve serotonin transmission arising from 
the DRN and involving different serotonin receptors and terminal 
regions [e.g., Ref. (158–161)]. Interestingly, CRF receptors are well 
established critical modulators of serotonin function in the dorsal 
raphé [e.g., Ref. (57, 58, 162), for reviews], and we have observed a 
critical role for raphé CRFR1 in the modulation of alcohol-related 
aggression in male mice (145). Systemic administration of two 
different CRFR1 antagonists (CP-154,526 and MTIP) was shown 
to dose-dependently reduce aggression not only in mice that 
were consuming a low dose of alcohol (1.0 g/kg) but also in mice 
under control conditions (after water drinking). However, when 
the CRFR1 antagonists were administered intra-dorsal raphé, a 
selective reduction in alcohol-escalated aggression was reported, 
with no other effects on species-typical aggressive behavior (145). 
Furthermore, the anti-aggressive effects of CP-154,526 seem to 
rely upon serotonin transmission, with increased serotonin 
output to the prefrontal cortex as a result of CRFR1 antagonism 
in alcohol-drinking animals (145).
Alcohol withdrawal-induced effects on 
Anxiety-Like Behaviors
In models with extensive and prolonged exposure to alcohol 
(e.g., alcohol vapor chamber or feeding from an alcohol-
containing liquid diet), animals may present alcohol withdrawal 
TABLe 2 | Pharmacological manipulations of CRF/urocortin targets on alcohol-related behaviors.
Target Drug (action,  
route adm.)
experimental design/treatment Results Reference
Behavioral sensitization
CRFR1 CP-154,526 
(antagonist, ip)
DBA/2J mice. Ethanol injections (2.5 g/kg, ip) for 
10 days, followed by ethanol challenge (1.5 g/kg, ip). 
Pretreatment with antagonist during acquisition or 
expression of behavioral sensitization
CRFR1 antagonist blocked the expression of 
ethanol-induced locomotor sensitization when 
administered prior to the challenge, but not during 
repeated ethanol treatment (induction)
Fee et al. 
(141)
DBA/2J mice. Ethanol injections (2.5 g/kg, ip) for 
10 days, followed by ethanol challenge (1.5 g/kg, ip). 
Pretreatment with antagonist during acquisition or 
expression of behavioral sensitization
CRFR1 antagonist blocked ethanol-induced 
locomotor sensitization when administered during 
the induction phase or prior to the challenge 
(expression)
Pastor et al. 
(139)
Aggression
CRFR1 CP-154,526 or MTIP 
(antagonist, ip)
CFW Swiss-derived mice. Operant ethanol self-adm 
(1.0 g/kg, oral, ~twice/week for 6 weeks); antagonist 
injection immediately after drinking, 10 min before 
aggressive confrontation
Reduced alcohol-escalated aggression and species-
typical aggression
Quadros 
et al. (145)
CP-154,526 or MTIP 
(antagonist, into 
DRN)
CFW Swiss-derived mice. Operant ethanol self-adm 
(1.0 g/kg, oral, ~twice/week for 6 weeks); antagonist 
infusion immediately after drinking, 10 min before 
aggressive confrontation
Selective reduction of alcohol-escalated aggression, 
with no effect on species-typical aggressive 
behaviors
Quadros 
et al. (145)
elevated plus maze
CRFR1 MTIP (antagonist,  
ip)
Wistar and msP rats. Ethanol injection (3 g/kg, ip) 
administered 12 h before elevated plus maze test. 
Antagonist administered 30 min prior test
Reduction of anxiogenic effects elicited by acute 
ethanol withdrawal
Gehlert et al. 
(96)
CRFR1/2 Alfa-helical CRF 
(9–41) (antagonist, 
icv)
Wistar rats. Ethanol liquid diet (2–3 weeks); antagonist 
administered 8 h into ethanol withdrawal. Anxiety-like 
behavior tested 30 min after drug adm
Reduction of anxiogenic effects elicited by ethanol 
withdrawal
Baldwin 
et al. (146)
Wistar rats. Ethanol liquid diet (16 days); antagonist 
administered 8 h into ethanol withdrawal. Anxiety-like 
behavior tested 30 min after drug adm
No change in the anxiogenic effects induced by 
ethanol withdrawal
Rassnick 
et al. (147)
Alfa-helical CRF 
(antagonist, into 
CeA)
Wistar rats. Ethanol liquid diet (16 days); antagonist 
administered 8 h after ethanol withdrawal. Behavioral test 
conducted 30 min after drug adm
Reduction of anxiogenic effects elicited by ethanol 
withdrawal
Rassnick 
et al. (147)
d-Phe-CRF 
(antagonist, icv)
Wistar rats. Ethanol liquid diet (21 days) + 6 weeks 
withdrawal; antagonist administered prior to restraint 
stress (15 min of stress). Elevated plus maze test was 
conducted after exposure to the stressor
Conditions of protracted abstinence and restraint 
stress, per se, failed to affect anxiety-like behavior. 
When combined, restraint stress-induced anxiogenic 
effects in animals preexposed to ethanol, which was 
attenuated by the antagonist
Valdez et al. 
(148)
CRFR2 Ucn 3 (agonist, icv) Wistar rats. Operant self-adm (daily 30-min session, 
22 days) followed by ethanol liquid diet (21 days). Agonist 
administered 2 h into ethanol withdrawal. Elevated plus 
maze was conducted 10 min after drug adm
Reduction of anxiogenic effects elicited by ethanol 
withdrawal
Valdez et al. 
(113)
Social interaction
CRFR1 CP-154,526 
(antagonist, ip)
Sprague-Dawley rats. Ethanol liquid diet (3 weeks, 
5 days/week); antagonist administered 4 h after ethanol 
removal, during first two withdrawal periods. Restraint 
stress (45 min) was applied 3 days after the final ethanol 
withdrawal. Social interaction test 30 min after stress
The antagonist reduced social avoidance promoted 
by ethanol withdrawal in combination with an acute 
stressor
Breese et al. 
(149)
Sprague-Dawley rats. Ethanol liquid diet (3 weeks, 
5 days/week); antagonist administered 4 h after ethanol 
removal, during first two withdrawal periods. Social 
interaction test 5–48 h after final ethanol withdrawal
5-h into ethanol withdrawal, social avoidance was 
reduced by the antagonist. Neither 24 or 48 h of 
withdrawal produced social deficits
Wills et al. 
(150)
Sprague-Dawley rats. Ethanol liquid diet (3 weeks, 
5 days/week); antagonist administered 4 h after ethanol 
removal, during first two withdrawal periods. Social 
interaction test conducted 5 h after the final ethanol 
withdrawal
The antagonist blocked social avoidance induced by 
ethanol withdrawal
Overstreet 
et al. (91)
CRFR1 CP-154,526 
(antagonist, ip)
P rats. Ethanol liquid diet (3 weeks, 5 days/week); 
antagonist administered 4 h after ethanol removal, during 
first two withdrawal periods. Social interaction test 
conducted 5–6 h after the final ethanol withdrawal
Antagonist blocked ethanol-withdrawal-induced 
social anxiety in P rats
Overstreet 
et al. (151)
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(Continued)
Target Drug (action,  
route adm.)
experimental design/treatment Results Reference
CRFR1 CRA-(1000) 
(antagonist, ip)
Sprague-Dawley rats. Control liquid diet (11 days) with 
two non-consecutive days of restraint stress (60 min; 
days 6 and 11). Antagonist administered 30 min before 
restraint stress. Starting on day 12, animals received 
ethanol liquid diet (5 days). Social interaction tested 5 h 
into ethanol withdrawal
The antagonist prevented the facilitatory effect of 
stress on ethanol-withdrawal anxiety
Breese et al. 
(152)
Sprague-Dawley rats. Ethanol liquid diet (17 days); drug 
administered 30 min before social interaction test (5–6 h 
into ethanol withdrawal)
The antagonist blocked ethanol-withdrawal-induced 
social anxiety
Knapp et al. 
(153)
Sprague-Dawley rats. Ethanol liquid diet (3 weeks, 
5 days/week); antagonist administered 4 h into ethanol 
withdrawal, during the first two withdrawal periods, or 
30 min before social interaction test (5 h into final ethanol 
withdrawal)
The antagonist reduced ethanol-withdrawal-
induced social anxiety, when administered during 
the first withdrawal periods (preventing withdrawal 
sensitization), or 30 min prior to the social interaction 
test
Overstreet 
et al. (91)
CRFR1 SSR 125543 
(antagonist, into 
CeA, DRN, or dorsal 
BNST)
Sprague-Dawley rats. Control liquid diet (12 days) with 
two non-consecutive days of restraint stress (60 min; 
days 6 and 12). Antagonist infused 15 min before 
restraint stress. Then, exposure to ethanol liquid diet 
(5 days). Social interaction test 5–6 h into ethanol 
withdrawal
Infusion of a CRFR1 antagonist into CeA, DRN, and 
dorsal BNST prevented the stress-potentiation of 
ethanol-withdrawal anxiety
Huang et al. 
(154)
SSR 125543 
(antagonist, into 
DRN, amygdala, 
or NAcc)
Inbred alcohol-preferring (iP) rats. Single-bottle 
continuous access (3 days), then two-bottle choice 
continuous access (3 weeks; 5 days/week). Antagonist 
administered 15 min before restraint stress (60 min), 
which occurred 4 h into ethanol withdrawal, during the 
first two withdrawal periods. Social interaction 5–6 h after 
the final ethanol withdrawal
Infusion of the antagonist into DRN and amygdala 
prevented social avoidance induced by the 
combination of ethanol withdrawal and restraint 
stress. No effects of the antagonist when infused into 
the NAcc
Knapp et al. 
(99)
SSR 125543 
(antagonist, ip)
Sprague-Dawley rats. Control liquid diet (13 days) with 
two non-consecutive days of cytokine or chemokine 
treatment (days 7 and 13). Antagonist administered 
15 min before treatment. Then, animals received ethanol 
liquid diet (5 days). Social interaction tested 24 h into 
ethanol withdrawal
Pretreatment with cytokine or chemokine elicited 
social anxiety after withdrawal from short-term 
exposure to ethanol. Social avoidance was 
prevented by the CRFR1 antagonist given during 
pretreatment phase
Knapp et al. 
(155)
CRFR1/2 CRF (agonist, icv) Sprague-Dawley rats. Control liquid diet with two 
non-consecutive days of CRF infusion (days 1 and 
6). Then, animals received ethanol liquid diet (5 days). 
Social interaction test was conducted 5 h into ethanol 
withdrawal
Pretreatment with CRF increased the social anxiety 
induced by withdrawal from one cycle of ethanol 
exposure
Overstreet 
et al. (91)
CRFR1/2 CRF (agonist, into 
DRN, amygdala, 
NAcc, VTA, or PVN)
Inbred alcohol-preferring (iP) rats. Single-bottle 
continuous access (3 days), then two-bottle choice 
continuous access (3 weeks; 5 days/week). CRF 
given 4 h into ethanol withdrawal during the first two 
withdrawal periods. Social interaction test 5–6 h into final 
ethanol withdrawal
Infusion of CRF into DRN or amygdala increased 
ethanol withdrawal-induced social anxiety. No effects 
after CRF infusion into NAcc, VTA, or PVN
Knapp et al. 
(99)
CRF (agonist, into 
CeA, BLA, DRN, 
dBNST, vBNST, 
hippocampus CA1, 
or PVN) and SSR 
125543 (CRFR1 
antagonist, ip)
Sprague-Dawley rats. Control liquid diet (12 days) with 
two non-consecutive days of CRF injection on different 
brain sites (days 6 and 12). In other experiments, 
CRFR1 antagonist was administered (ip) 15 min before 
CRF infusion. Then, animals received ethanol liquid 
diet (5 days). Social interaction test 5–6 h into ethanol 
withdrawal
Pretreatment with CRF into CeA, DRN, BLA, or 
dorsal BNST increased ethanol withdrawal-induced 
social anxiety. No effects when CRF was infused 
into ventral BNST, CA1, or PVN. The administration 
of the CRFR1 antagonist prevented the enhanced 
withdrawal anxiety induced by CRF infusions into 
CeA, DRN, and dorsal BNST
Huang et al. 
(154)
CRFR2 Antisauvagine-30 
(antagonist, icv)
Sprague-Dawley rats. Ethanol liquid diet (3 weeks, 
5 days/week); antagonist administered 4 h into ethanol 
withdrawal, during the first two withdrawal periods. 
Social interaction test 5 h into final ethanol withdrawal
No effects in ethanol withdrawal-induced social 
anxiety
Overstreet 
et al. (91)
Ucn 3 (agonist, icv) Sprague-Dawley rats. Control liquid diet (12 days) with 
two non-consecutive days of CRF injection (days 6 and 
12). Then, animals received ethanol liquid diet (5 days). 
Social interaction test 5–6 h into ethanol withdrawal
No effects on ethanol withdrawal-induced social 
anxiety
Huang et al. 
(154)
ip, intraperitoneal; icv, intracerebroventricular; CeA, central nucleus of the amygdala; BLA, basolateral amygdala; DNR, dorsal raphe nucleus; PVN, paraventricular nucleus of the 
hypothalamus; BNST, bed nucleus of the stria terminalis (d, dorsal; v, ventral); VTA, ventral tegmental area; NAcc, nucleus accumbens.
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effects within a few hours or days post termination of alcohol 
treatment, as well as protracted abstinence signs. Increases in 
anxiety-like behavior are a well characterized consequence 
of alcohol withdrawal, particularly within the first hours of 
withdrawal. Using the elevated plus maze, withdrawal-induced 
anxiety-like behavior was attenuated by icv administration of 
the non-selective CRFR1/R2 antagonist, alpha-helical CRF 
(146). However, a subsequent study only observed anti-anxiety 
effects when alpha-helical CRF was injected into the CeA, but 
not icv (147). In protracted abstinence from a 3-week alcohol 
exposure, anxiogenic effects in the plus maze emerged upon 
exposure to a stressor, selectively in alcohol “dependent” 
subjects. This effect was prevented by centrally blocking CRF 
receptors prior to the stressor (148). Specific roles for CRFR1 
or CRFR2 mechanisms in this particular model are still 
inconclusive. On the one hand, the activation of CRFR2 with 
urocortin 3 reduced anxiety behavior after withdrawal from 
chronic alcohol (113). On the other hand, selectively blocking 
CRFR1 receptors reduced anxiety-like behavior after withdrawal 
from a single alcohol injection (96).
A greater number of studies addressed social anxiety as an 
index of alcohol withdrawal, as assessed in social interaction 
tests, as shown in Table  2. Most commonly, these studies 
exposed rats to an alcohol liquid diet, with a single or repeated 
cycles of withdrawal (e.g., one cycle consists of 5 days of alcohol 
diet, followed by 2  days of alcohol withdrawal). This protocol 
promotes reduced social interaction when animals are tested 
a few hours into withdrawal, usually after the third cycle 
of alcohol exposure (see experimental designs on Table  2). 
Pharmacological antagonism of CRFR1 consistently attenuates 
repeated alcohol-withdrawal-induced social anxiety. Different 
CRFR1 antagonists are effective in reducing social avoidance 
when administered shortly prior to the social interaction test 
[e.g., Ref. (91, 149, 153)]. Interestingly, blocking CRFR1 signal-
ing during the initial withdrawal days of the cycles of alcohol 
exposure/withdrawal also prevents the typical social avoidance 
response, even though animals are tested in the absence of 
the antagonist [e.g., Ref. (91, 149–151)]. This suggests that 
cumulative neuroadaptations involving CRF occur over the 
repeated cycles of exposure and withdrawal, and by blocking 
CRFR1 receptors attenuates the deleterious effects of withdrawal 
on social anxiety. A few brain regions have been shown to 
participate in the CRFR1 modulation of withdrawal-related 
anxiety, including the DRN and the CeA, but not the nucleus 
accumbens (99).
Furthermore, exposure to stressors or to an infusion of CRF 
may additionally aggravate alcohol withdrawal-related social 
anxiety with a single cycle of alcohol diet exposure (91, 154), or 
with a two-bottle choice protocol (99). Infusion of CRF directly 
into the DRN, CeA, BNST, and the basolateral amygdala (BLA), 
either prior to alcohol exposure or during withdrawal periods 
of drinking cycles, also potentiates social avoidance associated 
with alcohol withdrawal (99). These effects of CRF are likely 
mediated by CRFR1, since urocortin 3 infusion does not repli-
cate the CRF potentiation of alcohol withdrawal (154), neither 
does a CRFR2 antagonist block withdrawal-induced social 
anxiety (91).
CONSeQUeNCeS OF ALCOHOL 
eXPOSURe ON THe CRF/
UROCORTiN SYSTeM
Extensive and consistent evidence supports alcohol’s actions on 
the CRF systems, modulating both HPA axis function as well 
as extra-hypothalamic CRF signaling in different brain regions. 
However, as shown in Table 3, consequences of alcohol exposure 
on CRF/urocortin system and the HPA axis may vary according 
to several variables, such as the route of alcohol administration, 
duration of alcohol exposure, alcohol withdrawal period, age, 
sex, animal strain, and CRF-related targets. Because the primary 
interest of this review is focused on alcohol and CRF-related 
peptides and signaling, data on ACTH and corticosterone were 
only included from studies that also directly assessed CRF-related 
targets. For reviews analyzing alcohol’s effects on HPA axis, with 
focus on glucocorticoid systems, please refer to Rose et al. (163), 
Stephens and Wand (2), and Edwards et al. (3).
As shown in Table 3, acute alcohol exposure, whether admin-
istered ip or by gavage, promotes activation of the HPA axis, as 
evidenced by dose-dependent increases on plasma ACTH and 
corticosterone with doses of 1 g/kg and higher [e.g., Ref. (41, 
164, 169, 172)]. Increases in ACTH can also be elicited with icv 
administration of alcohol (174) and can be shown in vitro in a 
hypothalamus–pituitary preparation (166). Importantly, alco-
hol’s actions on ACTH and corticosterone release seem to be 
primarily mediated by alcohol-induced CRF activation in the 
hypothalamus [see review by Rivier (192)]. Pretreatment with 
antagonists of CRF receptors as well as with anti-CRF antibody, 
both prevent or attenuate alcohol-induced increases in ACTH 
and corticosterone [e.g., Ref. (164, 165, 174)]. Consistent with 
this hypothesis, heteronuclear RNA (precursor of mRNA) for 
CRF and CRF peptide levels are reliably increased in the hypo-
thalamus after acute alcohol administration (164, 169, 174, 176). 
Hypothalamic CRF mRNA levels are not as reliably affected 
by acute alcohol, perhaps due to the kinetics of transcription 
processes (172, 176). In hypothalamic cell culture, alcohol 
incubation produced increases in CRF mRNA, CRF promoter 
activity, as well as CRF peptide, in a process that requires ade-
nylate cyclase-PKA signaling (186). Extra-hypothalamic sites, 
such as the central amygdala, also show augmented release of 
CRF peptide as a result of acute alcohol administration (184). 
Concerning CRF receptors, mRNA levels may be affected by 
acute alcohol exposure, but results are scarce and inconsistent 
(172, 176), as shown in Table 3.
Chronic or repeated alcohol exposure promote less consistent 
changes on CRF/urocortin function, when components of the 
CRF system are analyzed under alcohol influence or immediately 
(within 60 min) after removal from alcohol exposure. Some reports 
suggest the development of tolerance in HPA axis responses after 
repeated alcohol treatment, with lower ACTH and corticosterone 
responses to alcohol [e.g., Ref. (172, 175); but see Ref. (41, 167, 
168)]. Concerning CRF contents in the hypothalamus and/or 
pituitary, there are reports of no changes (41, 172), decreases (41, 
166, 177, 178), or increases (170) in CRF peptide, mRNA, and/or 
hnRNA after chronic alcohol. For example, in the PVN, alcohol-
induced upregulation of CRF hnRNA and alcohol-induced CRF 
TABLe 3 | Consequences of ethanol exposure on CRF/urocortin systems.
Target Tissue/brain 
region
ethanol administration withdrawal  
period
Other manipulations Animal/age Results Reference
ACTH Blood ip injection: acute (3 g/kg) 0–3 h Astressin (non-selective 
CRF receptor antagonist; 
3 mg/kg iv)
Rats: Sprague-Dawley 
(male) – adult
Acute ethanol increases ACTH levels (peak at 
30 min; baseline restored after 3 h). ACTH response 
to ethanol is blunted by pretreatment with astressin
Rivier and 
Lee (164)
ACTH Blood ip injection: acute 1.5–3 g/kg 0–30 min Non-selective CRF receptor 
antagonists: α-helical 
CRF9–41 (25 μg, icv) and 
astressin (0.3–3 mg/kg, iv)
Rats: Sprague-Dawley 
(male) – adult
Acute ethanol increased ACTH levels, with peak 
15 min after ethanol injection. Pretreatment with 
astressin attenuated the increased ACTH response 
to ethanol. Prior injection of α-helical CRF failed to 
alter ethanol-induced ACTH response
Rivier et al. 
(165)
ACTH Pituitary Acute ethanol exposure in 
hypothalamic–pituitary superfusion 
or pituitary superfusion (various 
concentrations)
During acute ethanol 
incubation
Rats: Sprague-Dawley 
(male) – adult
Incubation of hypothalamus–pituitary superfusion 
with acute ethanol produced dose-dependent 
increases on ACTH release (peak at 20 mg % 
ethanol). Acute ethanol on pituitary superfusion also 
produced increased ACTH release (peak at 40 mg 
% ethanol)
Redei et al. 
(166)
ACTH, 
CORT
(A) and (B) 
blood (C) 
pituitary-
derived cells
(A) ip injection: acute 0.3–3 g/kg (A) 15-min 
postinjection
Anti-CRF serum, CRF 
(0.004–2.5 nM)
Rats: Sprague-Dawley 
(male) – adult
(A) Lowest dose of ethanol (0.3 g/kg) increased 
CORT but not ACTH levels, while 1 and 3 g/kg 
induced high levels of both hormones. Previous 
administration of anti-CRF serum abolished ethanol-
induced ACTH release. (B) Higher concentrations of 
ethanol increased CORT secretion upon immediate 
withdrawal. (C) Acute exposure to 0.2% ethanol 
failed to affect CRF-induced ACTH release, but 
prolonged exposure (24 h) declined CRF-induced 
ACTH response
Rivier et al. 
(41)
(B) Vapor chamber: 7 days 
(various concentrations)
(B) Immediately 
after removal from 
chamber
(C) Cell culture incubation: 
exposure to acute ethanol (during 
incubation with CRF – 4 h) or 
prolonged ethanol (24 h prior to 
CRF incubation)
(C) Immediately after 
incubation
ACTH, 
CORT
Blood ip injection: acute 1–3 g/kg 30 min–4 h Rats: Sprague- 
Dawley – adult
Acute ip and ig injection of ethanol (2 and 3 g/kg) 
increased plasma ACTH levels, with peak release 
30 min after injection; returning to basal levels in 
180 min. Liquid diet: ethanol-fed rats presented 
lower levels of ACTH than pair-fed animals, but both 
groups presented similar plasma CORT response
Ogilvie et al. 
(167, 168)Intragastric injection: acute  
1–3 g/kg
Liquid diet: 4 or 6 nights  
(12 h/day)
ACTH, 
CORT
Blood Oral gavage (1 ml, 75% ethanol)a 0–1 h Rats: Wistar  
(male) – adult
Ethanol increased plasma ACTH (peak at 16 min) 
and CORT levels (peak at 5 min and elevation 
remains for 60 min)
Laszlo et al. 
(169)
ACTH, 
CORT
Blood Vapor chamber: 7 days 3 h iv CRF (0.3–10 μg) or 
footshock (1.0 mA, 0.5 s, 
2 shocks/min; during 
10 min)
Rats: Sprague-Dawley 
(male) – adult
At 3-h withdrawal, ethanol-exposed rats showed 
higher levels of ACTH and CORT. After CRF 
stimulation, controls show dose-dependent 
increases in ACTH levels, while ethanol-exposed 
rats showed increases in ACTH with no dose 
dependency. At the highest CRF dose, ethanol-
exposed rats showed lower ACTH response than 
controls. Footshock induced similar ACTH response 
in both groups
Rivier et al. 
(170)
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Target Tissue/brain 
region
ethanol administration withdrawal  
period
Other manipulations Animal/age Results Reference
ACTH, 
CORT
Blood, pituitary Vapor chamber: 7 days during 
the second gestational week. 
Pups were fed by foster mothers 
and euthanized at 21 days old. 
Pituitary maintained in short-term 
culture
28 days Exposure to inescapable 
shocks (1.5 mA, 1 s, 25 
times over 10 min) when 
pups were 21 days old, 
prior to euthanasia; CRF 
(0.01–100 nM)
Rats: Sprague-Dawley – 
prenatal/pup
Ethanol exposure during the second week of 
gestation potentiated plasmatic ACTH but not 
CORT response to shock stress. The ACTH 
released from the pituitary of ethanol-exposed pups 
was decreased after 3 h incubation with CRF and 
increased after incubation with higher CRF dose, 
when compared with control pups
Lee et al. 
(171)
ACTH, 
CORT, 
POMC 
(mRNA)
Blood, 
pituitary, and 
hypothalamus
Oral gavage: (4.5 g/kg/day) – 1 or 
14 days
30 min after last adm Rats: Fischer (male) –  
adult
Ethanol-induced acute increases in ACTH and CORT 
levels. After 14 days, ethanol’s effects on ACTH 
were abolished and CORT responses were reduced. 
Neither protocol changed POMC mRNA levels in 
pituitary. Hypothalamic POMC mRNA levels were 
reduced after acute, but not chronic ethanol
Zhou et al. 
(172)
ACTH, 
CORT; 
POMC 
(mRNA)
Blood, pituitary Liquid diet (gestational): ethanol 
(~13 g/kg/day) during all 
pregnancy (withdrawal upon birth)
~4 months (exposure 
during prenatal 
period; tissue 
collected as adults)
Rats: Sprague-Dawley 
(male and female) –  
prenatal/adult
Prenatal ethanol exposure failed to affect plasmatic 
CORT and ACTH levels, or pituitary POMC mRNA
Glavas 
et al. (173)
ACTH, 
POMC 
(hnRNA 
and 
mRNA)
Blood, pituitary ip injection: acute (3 g/kg) 0–60 min after 
ethanol adm
CRF antibody (0.4 ml/kg) Rats: Sprague-Dawley 
(male) – adult
ACTH: both ip and icv ethanol injection induced 
increased plasma ACTH levels, a response that 
was prevented by anti-CRF antibody pretreatment. 
POMC: pituitary POMC primary transcript is 
increased 15, 30, and 60 min after ethanol ip 
and 15 min after ethanol icv. Anti-CRF antibody 
attenuated ethanol-induced POMC transcription
Lee et al. 
(174)icv injection: (5 μl)
CORT Blood Vapor chamber: 6 h daily, during 2 
or 8 days (in adolescence)
Immediately after 
removal from 
chamber, ranging 
from 1.5 to 5.5 h of 
vapor exposure
Rats: Sprague-Dawley 
(male) – adolescent
On the 2nd day of ethanol vapor exposure, 
adolescent rats presented increased levels of CORT 
after 3.5 and 5.5 h of ethanol vapor. On the 8th day, 
CORT levels were increased after exposure of 4.5 
and 5.5 h to ethanol vapor
Logrip et al. 
(175)
CRF 
(hnRNA 
and 
mRNA)
Parvicellular 
PVN
Ip injection: acute (3 g/kg) 3 h Astressin (non-selective 
CRF receptor antagonist; 
15 μg, icv)
Rats: Sprague-Dawley 
(male) – adult
CRF heteronuclear RNA was increased after ethanol, 
as well as the combination of ethanol + astressin. 
CRF mRNA levels were unaffected
Lee and 
Rivier (176)
CRF 
(hnRNA 
and 
mRNA)
Parvicellular 
PVN
Ip injection: acute (3 g/kg) 20 min–3 h Rats: Sprague-Dawley 
(male) – adult
CRF heteronuclear RNA was increased at 20 and 
40 min after ethanol administration. CRF mRNA 
levels were unaffected
Rivier and 
Lee (164)
CRF 
(hnRNA 
and 
peptide)
PVN, median 
eminence (ME)
Intragastric injection: daily (4.5 g/
kg), 3 days of treatment, ethanol 
challenge 7 days later
0–1 h Rats: Sprague-Dawley 
(male) – adult
In PVN: ethanol pretreatment did not affect basal 
CRF hnRNA levels. Preexposure to ethanol reduced 
ethanol-induced upregulation of CRF hnRNA. In 
medial eminence (external zone): reduced CRF 
peptide levels in rats with prior ethanol history (after 
7 days withdrawal)
Lee et al. 
(177, 178)
CRF 
(hnRNA)
Parvicellular 
PVN
Icv injection: acute (5 μl) 0–60 min after 
ethanol adm
Rats: Sprague-Dawley 
(male) – adult
PVN CRF hnRNA is increased 30 min after ethanol 
treatment
Lee et al. 
(174)
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Target Tissue/brain 
region
ethanol administration withdrawal  
period
Other manipulations Animal/age Results Reference
CRF 
(mRNA)
BLA Intermittent ethanol drinking: daily 
access to one-bottle ethanol 
for 1 h, during 18 days, under 
water restriction condition. Intake 
~2.5 g/kg/day for adolescents; 
~2.3 g/kg/day for adults
60 days Rats: Long-Evans 
(male) –  
adolescent – adult
BLA pre-pro-CRF mRNA levels were decreased in 
rats exposed to ethanol during adulthood, but not in 
those exposed during adolescence
Falco et al. 
(179)
CRF 
(mRNA)
CeA Liquid diet: for 10–12 days (intake 
~11.5 g/kg/day)
Immediately after 
ethanol removal
Rats: Sprague-
Dawley (male) – 120 g 
(~5 weeks old)
Ethanol liquid diet increased pre-pro-CRF mRNA 
levels in CeA
Lack et al. 
(23)
CRF 
(mRNA)
CeA Vapor chamber: intermittent 
exposure (8 h ethanol vapor/8 h 
air), for 8 on/off cycles. Ethanol 
(1.6 g/kg, ip) injected prior to 
every ethanol vapor session. 
Stress-induced ethanol self-adm 
(60-min session for 4 days; 
120 min in the last session)
Immediately after 
removal from ethanol 
exposure; 2 weeks 
withdrawal; 2 weeks 
withdrawal + 4 h 
after the final self-
adm session
4-h food restriction prior to 
ethanol self-adm sessions
Mice: C57BL/6N  
(male) – adult
Immediately after ethanol vapor exposure, there 
were no changes in CeA CRF mRNA levels. After 
2 weeks of withdrawal, CeA CRF mRNA levels were 
increased, with further increases 4 h after the last 
drinking session
Eisenhardt 
et al. (180)
CRF 
(mRNA)
CeA, BNST Vapor chamber: 7 weeks of 
ethanol exposure (17 h/day)
3 weeks Rats: Wistar 
(male) –adult
Chronic ethanol exposure increased CRF mRNA 
levels in CeA, but not in BNST
Sommer 
et al. (18)
CRF 
(mRNA)
Hypothalamus Oral gavage (4.5 g/kg/day) – 1 or 
14 days
30 min after final adm Rats: Fischer 
(male) – adult
No changes in CRF mRNA levels after acute or 
chronic ethanol
Zhou et al. 
(172)
CRF 
(mRNA)
Hypothalamus Vapor chamber: 7 days during the 
second gestational week. Pups 
were fed by foster mothers and 
euthanized at 21 days old
28 days Rats: Sprague- 
Dawley – prenatal/ 
pup
Ethanol exposure during the second week of 
gestation increased hypothalamic CRF mRNA levels 
in the offspring
Lee et al. 
(171)
CRF 
(mRNA)
Parvicellular 
PVN
Liquid diet (gestational): ethanol 
(~13 g/kg/day) during all 
pregnancy (withdrawal upon birth)
~4 months (exposure 
during prenatal 
period; tissue 
collected as adults)
Rats: Sprague-Dawley 
(male and  
female) – prenatal/ 
adult
Prenatal ethanol exposure failed to affect CRF mRNA 
levels in parvicellular PVN in males and females, 
when adults
Glavas 
et al. (173)
CRF 
(mRNA)
Parvicellular 
PVN
Vapor chamber: 7 days Immediately after 
removal from 
chamber
Rats: Sprague-Dawley 
(male) – adult
Increased CRF mRNA levels in PVN after 3 or 7 days 
of ethanol vapor exposure
Rivier et al. 
(170)
CRF 
(mRNA)
PVN Vapor chamber: 6 h daily, during 
15 days (in adolescence). Also, 
20 days later, rats received 
intragastric ethanol (4.5 g/kg) 
challenge
2 h after ethanol 
challenge (adulthood)
Rats: Sprague-Dawley 
(male) – adolescent/
adult
Rats exposed to ethanol vapor during adolescence 
presented decreased levels of CRF mRNA in PVN 
after ethanol challenge in adulthood
Allen et al. 
(181)
CRF 
(mRNA)
PVN Vapor chamber: 6 h daily, during 
8 or 15 days (in adolescence). 
Also, 20 days later, rats received 
intragastric ethanol (4.5 g/kg) 
challenge
6 h after 8 or 15 days 
of vapor exposure 
(adolescence); or 
2 h after ethanol 
challenge (adulthood)
Rats: Sprague-
Dawley (male and 
female) – adolescent/
adolescent-adult
During adolescence, there were no differences in 
PVN CRF mRNA levels after ethanol vapor exposure. 
Adolescent ethanol vapor exposure also failed to 
affect CRF mRNA levels in adult rats exposed to an 
ethanol challenge after 20 days of withdrawal
Logrip et al. 
(175)
CRF 
(peptide)
Amygdala Liquid diet: 2–3 weeks 2–12 h Rats: Wistar  
(male) –adult
10–12 h of withdrawal increases CRF 
immunoreactivity in amygdala dialyzates
Merlo-Pich 
et al. (182)
(Continued)
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ethanol administration withdrawal  
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CRF 
(peptide)
BNST Liquid diet: ethanol for 2 weeks, 
~10 g/kg/day. Diet removal for 
7.5 h + reexposure to ethanol diet
0–7.5 h Rats: Long-Evans 
(male) – adult
Chronic ethanol had no effect on BNST CRF 
baseline levels (while still exposed to alcohol). During 
withdrawal, only ethanol-fed rats showed elevated 
levels of extracellular CRF in BNST, from 4.5 to 7.5 h. 
Upon reexposure to ethanol, CRF levels returned to 
baseline. Ethanol-fed animals exposed to control diet 
after abstinence, presented even further increases in 
CRF levels
Olive et al. 
(183)
CRF 
(peptide)
CeA Ip injection: acute (2–2.8 g/kg) Immediately –  
180 min
Rats: Sprague-Dawley 
(male) – adult
Doses of 2.4 and 2.8 g/kg induced increased release 
of CRF in the CeA 120 min after administration, the 
effect was sustained until 180-min postinjection
Lam and 
Gianoulakis 
(184)
CRF 
(peptide)
CeA, VTA Drinking in the dark: 1 cycle = 2-h 
ethanol access for 3 days, 4-h 
access in the 4th day. 3 days of 
withdrawal between cycles
0–24 h Mice: C57BL/6J  
(male) – adult
CRF immunoreactivity was increased in CeA 
immediately after 1 or 6 cycles of drinking; in VTA 
only after 1 cycle. CRF immunoreactivity was also 
increased 18–24 h after 3 cycles of drinking
Lowery-
Gionta et al. 
(73)
CRF 
(peptide)
Hypothalamus Drinking in the dark (prenatal 
exposure): two-bottle choice 
(ethanol in saccharin or saccharin 
alone), 4 h/day during all 
gestational period. Upon birth, 
dams were gradually weaned out 
of ethanol over 6 days
40–50 days (prenatal 
exposure; euthania in 
late adolescence)
Mice: C57BL/6J  
(male) – prenatal/
adolescent
Increased levels of CRF immunoreactivity in the 
hypothalamus of mice with prenatal ethanol 
exposure
Caldwell 
et al. (185)
CRF 
(peptide)
Hypothalamus Liquid diet: 2 weeks. 
Acute ethanol exposure in 
hypothalamic superfusion (various 
concentrations)
Immediately after 
ethanol removal
Rats: Sprague-Dawley 
(male) – adult
Chronic ethanol exposure increased CRF release 
pulse frequency in a hypothalamic in vitro 
preparation. CRF content in hypothalamus was lower 
in ethanol-exposed rats than in controls. Incubation 
with acute ethanol produced dose-dependent 
increases on CRF release from hypothalamus, 
effects that were blunted in ethanol diet-exposed 
rats. Potassium-stimulated CRF release was also 
reduced in ethanol preexposed rats
Redei et al. 
(166)
CRF 
(peptide)
Hypothalamus Oral gavage (1 ml, 75% ethanol)a 0–1 h Cycloheximide (protein 
synthesis inhibitor; 10 or 
30 mg/kg, ip)
Rats: Wistar  
(male) – adult
Ethanol increased hypothalamic CRF contents after 
30 and 60 min. Cycloheximide reduced ethanol-
induced CRF levels
Laszlo et al. 
(169)
CRF 
(peptide)
Median 
eminence, 
hypothalamus
Vapor chamber: 7 days (various 
concentrations of ethanol)
Immediately after 
removal from vapor 
chamber
Rats: Sprague-Dawley 
(male) – adult
Higher doses of ethanol reduced CRF 
immunoreactivity in median eminence, but not in 
hypothalamus
Rivier et al. 
(41)
CRF 
(promoter, 
mRNA 
and 
peptide)
Hypothalamic 
cell culture
Ethanol incubation (25 mM, during 
1–4 h)
Immediately after 
ethanol incubation
Forskolin (adenylyl cyclase 
activator; 25 μM); PKA 
inhibitors H89 (10 μM), 
Rp-cAMP (250 μM)
Hypothalamic cells 
derived from  
Sprague-Dawley rats  
(6–7 days old)
Acute ethanol incubation increased CRF peptide 
levels (after 1 and 4 h), increased CRF mRNA (peak 
at 1 h incubation), and increased CRF promoter 
activity (after 2 h). These effects were potentiated 
with the combined incubation of ethanol and 
forskolin, except for ethanol-induced CRF mRNA, 
which was slightly blunted by forskolin. PKA 
inhibitors abolished the effects of ethanol incubation
Li et al. 
(186)
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ethanol administration withdrawal  
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CRF-BP 
(mRNA)
CeA Liquid diet: for 10–12 days (intake 
~11.5 g/kg/day)
Immediately after 
ethanol removal
Rats: Sprague-
Dawley (male) – 120 g 
(~5 weeks old)
No alterations in CRF-BP in the CeA after chronic 
ethanol exposure
Lack et al. 
(23)
CRFR1 
(mRNA)
Amygdala Extended ethanol drinking: three-
bottle choice (water, ethanol 5%, 
and ethanol 10%) during 70 days, 
followed by 2 weeks of withdrawal 
and reexposure to three-bottle 
choice for 2 weeks. Then, quinine-
adulterated ethanol for 2 weeks, 
followed by ethanol reexposure 
for 1 week
Immediately after 
the final ethanol 
exposure
Mice: Swiss  
(male) – adult
Mice with moderate ethanol intake profile (± 9.4 g/
kg/day) presented increased CRFR1 mRNA levels 
in amygdala, while animals with high (± 11.5 g/kg/
day) and low (± 5.2 g/kg/day) ethanol intake profile 
showed no alterations in CRFR1 mRNA
Correia 
et al. (83)
CRFR1 
(mRNA)
Amygdala Operant self-administration: 
after training lever-pressing for 
saccharin, 3 days of access to 
ethanol + saccharin solution (30-
min session/day; ~1 g/kg ethanol)
20 days Rats: Wistar  
(male) – adult
No correlations between alcohol consumption and 
CRFR1 mRNA expression in the amygdala
Pickering 
et al. (187)
CRFR1 
(mRNA)
CeA, MeA, 
BLA
Vapor chamber: intermittent 
exposure (8 h ethanol vapor/8 h 
air), for 8 on/off cycles. Ethanol 
(1.6 g/kg, ip) injected prior to 
every ethanol vapor session. 
Stress-induced ethanol self-adm 
(60-min session for 4 days; 
120 min in the last session)
Immediately after 
removal from ethanol 
exposure; 2 weeks 
withdrawal; 2 weeks 
withdrawal + 4 h 
after the final self-
adm session
4-h food restriction prior to 
ethanol self-adm sessions
Mice: C57BL/6N  
(male) – adult
Immediately after ethanol vapor exposure, CRFR1 
mRNA levels were decreased in CeA but increased 
after 2 weeks of withdrawal and 4 h after the last 
self-administration session. In MeA and BLA, CRFR1 
levels were also increased after withdrawal and after 
the drinking session
Eisenhardt 
et al. (180)
CRFR1 
(mRNA)
CeA, MeA, 
BLA, BNST
Vapor chamber: 7 weeks of 
ethanol exposure (17 h/day)
3 weeks Rats: Wistar  
(male) – adult
Chronic ethanol exposure increased CRFR1 mRNA 
in BLA and MeA, but not CeA and BNST
Sommer 
et al. (18)
CRFR1 
(mRNA)
CeA, MeA, 
BLA, Nacc, Cg
Two-bottle choice: continuous 
access to ethanol and water, 
24 h/day for 15 days
Immediately after 
ethanol removal
Rats: alcohol-preferring 
(msP) (male) – adult
Chronic ethanol consumption decreased CRFR1 
mRNA levels in CeA, MeA, and NAcc, but not in BLA 
or Cg
Hansson 
et al. (188)
CRFR1 
(mRNA)
DRN Drinking in the dark: three daily 
1-h sessions (2-h interval between 
sessions), 5 days/week, for 
3 weeks (intake ~9 g/kg/day)
3 h Rats: alcohol-preferring 
(P) (male) – adolescent
Increased CRFR1 mRNA in the DRN of ethanol 
binge-drinking rats
McClintick 
et al. (189)
CRFR1 
(mRNA)
Hypothalamus Operant self-administration: 
after training lever-pressing for 
saccharin, 3 days of access to 
ethanol + saccharin solution (30-
min session/day; ~1 g/kg ethanol)
20 days Rats: Wistar  
(male) – adult
Strong positive correlation of alcohol consumption 
and hypothalamic CRFR1 mRNA expression
Pickering 
et al. (190)
CRFR1 
(mRNA)
Parvicellular 
PVN
Intragastric injection: daily (4.5 g/
kg), 3 days of treatment, ethanol 
challenge 7 days later
3 h Rats: Sprague-Dawley 
(male) – adult/adult
Ethanol pretreatment did not affect basal CRFR1 
expression. Preexposure to ethanol reduced ethanol-
induced upregulation of CRFR1 mRNA
Lee et al. 
(177, 178)
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CRFR1 
(mRNA)
Pituitary Liquid diet (gestational): ethanol 
(~13 g/kg/day) during all 
pregnancy (withdrawal upon birth)
~4 months (exposure 
during prenatal 
period; tissue 
collected as adults)
Rats: Sprague-Dawley 
(male and female) –  
prenatal/adult
Prenatal ethanol exposure reduced CRFR1 mRNA 
levels in the anterior pituitary of male but not female 
rats
Glavas 
et al. (173)
CRFR1 
(mRNA)
Pituitary Oral gavage (4.5 g/kg/day) – 1 or 
14 days
30 min after final adm Rats: Fischer  
(male) – adult
Acute, but not chronic, ethanol reduced CRFR1 
mRNA in the anterior pituitary
Zhou et al. 
(172)
CRFR1 
(mRNA)
PVN, 
amygdala
Ip injection: acute (3 g/kg) 3 h Astressin (non-selective 
CRF receptor antagonist; 
15 μg, icv)
Rats: Sprague- 
Dawley (male) – adult
Ethanol increased CRFR1 mRNA in parvicellular 
PVN, an effect not prevented by astressin. In 
magnocellular PVN, CRFR1 mRNA is increased after 
combined ethanol plus astressin administration. 
No ethanol-induced changes in amygdala CRFR1 
mRNA levels
Lee and 
Rivier (176)
CRFR2 
(mRNA)
Amygdala Operant self-administration: 
after training lever-pressing for 
saccharin, 3 days of access to 
ethanol + saccharin solution (30-
min session/day; ~1 g/kg ethanol)
20 days Rats: Wistar (male) –  
adult
No correlations between alcohol consumption and 
CRFR2 mRNA expression in the amygdala
Pickering 
et al. (187)
CRFR2 
(mRNA)
CeA, MeA, 
BLA
Vapor chamber: intermittent 
exposure (8 h ethanol vapor/8 h 
air), for 8 on/off cycles. Ethanol 
(1.6 g/kg, ip) injected prior to 
every ethanol vapor session. 
Stress-induced ethanol self-adm 
(60-min session for 4 days; 
120 min in the last session)
Immediately after 
removal from ethanol 
exposure; 2 weeks 
withdrawal; 2 weeks 
withdrawal + 4 h 
after the final self-
adm session
4-h food restriction prior to 
ethanol self-adm sessions
Mice: C57BL/6N  
(male) – adult
Immediately after ethanol vapor exposure, there were 
no effects on CRFR2 mRNA levels in CeA. After 
2-week withdrawal, no changes were observed in 
CRFR2 mRNA levels in CeA, MeA, and BLA. Ethanol 
self-administration increased CRFR2 mRNA in CeA 
and BLA, but not in MeA in ethanol-exposed mice, 
relative to air-exposed controls
Eisenhardt 
et al. (180)
CRFR2 
(mRNA)
CeA, MeA, 
BLA, BNST
Vapor chamber: 7 weeks of 
ethanol exposure (17 h/day)
3 weeks Rats: Wistar  
(male) – adult
Chronic ethanol exposure decreased CRFR2 mRNA 
levels only in BLA
Sommer 
et al. (18)
CRFR2 
(mRNA)
DRN Drinking in the dark: three daily 
1-h sessions (2 h interval between 
sessions), 5 days/week, for 
3 weeks (intake ~9 g/kg/day)
3 h Rats: alcohol-preferring 
(P) (male) – adolescent
Decreased CRFR2 mRNA in the DRN of ethanol 
binge-drinking rats
McClintick 
et al. (189)
CRFR2 
(mRNA)
Hypothalamus Operant self-administration: 
after training lever-pressing for 
saccharin, 3 days of access to 
ethanol + saccharin solution (30-
min session/day; ~1 g/kg ethanol)
20 days Rats: Wistar (male) 
– adult
Strong positive correlation of alcohol consumption 
and hypothalamic CRFR2 mRNA expression
Pickering 
et al. (190)
CRFR2 
(mRNA)
VMH, SON Ip injection: acute (3 g/kg) 3 h Rats: Sprague-Dawley 
(male) – adult
CRFR2 mRNA in VHM or SON is not affected by 
ethanol
Lee and 
Rivier (176)
CRFR2 
(protein)
LS, DRN Ip injection: chronic (2 g/kg, daily), 
0, 1, or 7 days
24 h Mice: C57BL/6J  
(male) – adult
Higher CRFR2 binding in dorsomedial DR after 
7 days of ethanol exposure. No changes in LS
Weitemier 
and 
Ryabinin 
(191)
(Continued)
TABLe 3 | Continued
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release were reduced in rats with a history of alcohol exposure 
(166, 177, 178). In the CeA, repeated alcohol was reported to 
increase detection of CRF mRNA or immunoreactivity [(73, 
193); but see Ref. (188)], although a lack of alteration was also 
found (180). In amygdalar nuclei, a reduction in CRFR1 gene 
expression, but not CRFR2, was detected after alcohol vapor 
exposure (180) or after 15 days of voluntary of alcohol drinking 
in an alcohol-preferring strain (188). After extended access to 
alcohol for over 90 days, only mice with a profile of moderate 
alcohol intake showed increased CRFR1 mRNA in the amygdala, 
which was not the case for mice with high or low intake profiles 
(83). In the BNST, no changes in CRF immunoreactivity were 
seen while animals still had access to alcohol in a liquid diet, 
but increases in CRF emerged after 4  h into withdrawal from 
alcohol (183). Interestingly, repeated alcohol failed to change the 
number of urocortin1 cells in the Edinger–Westphal nucleus, but 
it decreased urocortin1 fibers to the lateral septum and the DRN 
(191).
Short-term withdrawal (here defined as an arbitrary window 
of 1–24 h after the final alcohol exposure) from repeated/chronic 
alcohol administration is usually associated with increased 
anxiety-like behavior and escalated alcohol self-administration, 
as discussed in previous sections. Acute withdrawal (i.e., 3 h) from 
a 7-day alcohol vapor exposure was characterized by increased 
plasma ACTH and corticosterone levels, and also associated with 
increased CRF mRNA levels in the PVN (170). However, maximal 
CRF-mediated ACTH response was reduced in alcohol-exposed 
rats (170). A different study showed that after 1-day withdrawal 
from chronic alcohol liquid diet, CRF immunoreactivity was not 
changed in the hypothalamus but was reduced in the amygdala, 
hippocampus, and frontal cortex (194). These changes were also 
accompanied by lower plasma corticosterone concentrations at 
acute withdrawal. In a classic study on acute alcohol withdrawal, 
dialyzate CRF levels in the amygdala are shown to increase in great 
proportions throughout the first 12 h of withdrawal from chronic 
alcohol vapor exposure (182). Increases in CRF immunoreactiv-
ity in CeA are also observed after repeated cycles of binge alcohol 
drinking in mice, persisting for 18–24 h into alcohol withdrawal 
(73). In another stress-related region, the BNST, CRF peptide 
levels increase after 4.5 h into withdrawal from an alcohol liquid 
diet. Remarkably, CRF levels in the BNST return back to baseline 
levels when rats regain access to the alcohol-containing liquid 
diet (183). However, these effects of acute alcohol withdrawal may 
be age-dependent. Exposure to alcohol vapor or binge drinking 
for 8–15  days in adolescent rats produces no changes in CRF 
transcripts or peptides in the PVN (175, 195), although a reduced 
CRF immunoreactivity in the CeA is observed (195). As shown 
in Table 3, a few studies also reported changes in CRF receptors’ 
transcripts after short-term alcohol withdrawal in the PVN (177, 
178) and the DRN (189), as well as in CRFR2 binding levels in 
the DRN (191).
Finally, critical adaptations in the CRF/urocortin are recruited 
during protracted abstinence from chronic alcohol exposure (i.e., 
at least 7 days of withdrawal, but usually longer than 2 weeks). 
For example, rat’s exposure to repeated alcohol administrations 
followed by a 7-day withdrawal, show reduced CRF peptide levels 
in the median eminence of the hypothalamus, despite no changes 
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in CRF or CRFR1 transcripts in the PVN (177, 178). However, 
animals preexposed to the drug show a blunted upregulation of 
CRF and CRFR1 transcripts in the PVN in response to an alcohol 
challenge (177, 178). These data, and others, support a dampened 
function of HPA axis function after chronic alcohol followed by 
prolonged withdrawal, which is also supported by evidence of 
low baseline corticosterone levels after 3-weeks withdrawal from 
chronic alcohol [e.g., Ref. (194)]. As shown in Table 3, prenatal 
exposure to alcohol also dysregulates elements of the HPA axis 
in adolescent and adults animals, although differences in neu-
roadaptations arise according to the duration and methodology 
of in utero alcohol exposure [e.g., Ref. (171, 173, 185)]. Chronic 
exposure to alcohol during adolescence may lead to reduced HPA 
axis response to alcohol in early adulthood, as shown by reduced 
CRF mRNA in the PVN (181). However, such outcome was not 
observed when adolescents were exposed to alcohol as binge 
drinking (195). Thus, recruitment of neuroadaptive changes in 
CRF/urocortin elements in the HPA axis depend on age of alcohol 
exposure, the duration and protocol for alcohol exposure (vapor, 
liquid diet, oral intake), as well as age at time of assessment of 
CRF/urocortin targets.
In the amygdala, and particularly within the CeA, there is 
consistent evidence of upregulated CRF signaling after protracted 
withdrawal from chronic alcohol exposure. For example, there are 
increased levels of CRF transcript in the CeA (18, 180) or immu-
noreactivity for CRF in the amygdala (194) after 3 or more weeks 
of withdrawal from alcohol. These changes are accompanied by 
increased CRFR1 gene expression within the CeA and/or in other 
amygdalar nuclei (BLA, MeA). Changes in CRFR2 transcripts in 
the amygdala were less consistent within different studies (18, 
180). One study also reported a decrease in CRF mRNA in the 
BLA in adult, but not adolescent rats after 18 days of restricted 
access to alcohol drinking followed by a 60-day withdrawal (179). 
Although BNST levels of CRF seem to be upregulated during 
acute withdrawal (183), BNST may not be particularly engaged 
in protracted abstinence, as no changes in transcripts for CRF or 
CRFR1 were seen in this region (18).
In summary, alcohol exposure importantly impacts CRF/
urocortin components and function, both within the HPA axis 
and in extra-hypothalamic sites. In general, acute alcohol reliably 
upregulates CRF transcripts and/or peptide within the hypo-
thalamus, promoting activation of the HPA axis with increases 
in ACTH and corticosterone. When CRF/urocortin signaling is 
assessed shortly after chronic alcohol exposure, relevant but quite 
variable and inconsistent effects may be detected, depending on 
brain region, alcohol exposure protocol, and the age of animals. 
After protracted abstinence from alcohol, a more reliable profile 
emerges, characterized by hyperactivity of brain CRF signaling, 
particularly within the amygdala. Although the studies are lim-
ited, existing research suggests the involvement of urocortins as 
targets for alcohol’s effects, as well as changes in CRFR2 mRNA/
protein levels, and therefore these molecules should be further 
investigated. Also, target brain regions were highly limited to the 
hypothalamus, amygdala, and BNST, with a few exceptions. A 
wider characterization of alcohol modulation of CRF/urocortin 
signaling should include the VTA, accumbens, DRN, prefrontal 
cortex, and other reward-related structures, which may contribute 
to our understanding of alcohol-induced neuroadaptations that 
influence alcohol reward and withdrawal.
iNvOLveMeNT OF CRF SYSTeMS iN 
HUMAN ALCOHOLiSM
This review will discuss a few human studies regarding HPA axis 
function in AUDs. For a vast discussion on this literature, we also 
recommend reviews by Lovallo (196); Rose et al. (163); Stephens 
and Wand (2). As described in animal studies, human studies 
confirm an activation of HPA axis by alcohol as demonstrated 
by increases in plasma cortisol after an acute alcohol adminis-
tration (197). This cortisol response seems to require ACTH 
release from the hypophysis, as alcohol failed to increase cortisol 
levels in patients with lesions in the anterior hypophysis (197). In 
heavy drinkers and dependent subjects, there is an attenuation 
of alcohol-induced cortisol response (198), as well as reduced 
cortisol and ACTH levels upon CRF stimulation (199–201). 
Dependent individuals also show an attenuated cortisol response 
to moderate mental and physical stressors (202–205). Upon 
alcohol withdrawal, plasma cortisol is elevated during the first 
week, but with protracted abstinence, cortisol levels drop below 
normal range (206–208). Together, these studies suggest a blunted 
HPA function in response to drugs and stressors in alcoholics, 
supporting a contribution of the HPA axis in the transition to 
dependence (209).
Studies targeting the CRF system and alcohol in humans mostly 
rely on genetic approaches, with evidence of associations between 
AUDs and polymorphisms in genes encoding for CRFR1 and 
CRF-BP. Chen et al. (210) showed that variations in the CRFR1 
gene are associated with alcohol dependence. In another study, 
patterns of alcohol consumption were assessed in a teenage sam-
ple, as well as in a sample of dependent adults. In teenagers with 
little to moderate alcohol exposure, polymorphisms in CRFR1 
gene were associated with the amount of alcohol consumed, but 
not with the frequency of drinking episodes (211). In alcohol-
dependent adults, an association was also detected between 
CRFR1 polymorphism and the amount of alcohol consumed 
(211). Different studies show gene–environment interactions, 
in which variants of the CRFR1 gene interact with a history of 
exposure to stressful events and predict heavy alcohol drinking 
(212, 213) and age of drinking initiation (213). On the other 
hand, protective effects for alcohol dependence were shown for a 
gene–environment interaction involving a CRFR1 haplotype and 
childhood sexual abuse in an Australian population (214).
Electroencephalogram phenotypes have been identified for 
anxiety-prone alcoholics (215, 216). A “linkage scan” indicated 
CRF-BP as a candidate gene for electroencephalogram profiles in 
two distinct populations. Further, genetic variations in CRF-BP 
were associated with anxiety disorders and AUDs (217). There is 
also evidence that polymorphisms in CRF-BP modulate stress-
induced craving in heavy drinkers (218) and are involved in the 
relationship between negative reactivity to stress and negative 
consequences to alcohol consumption (219). Thus, CRF-BP gene 
variations may play particular a role in stress-related alcohol 
dependence. Furthermore, an interaction of polymorphisms in 
CRFR1 and CRF-BP genes predicts increased risk for AUDs in 
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schizophrenic patients (220). Thus, genetic studies, so far, point 
to some polymorphisms in CRFR1 and CRF-BP genes, which can 
contribute to the susceptibility for AUDs.
SUMMARY AND PeRSPeCTiveS
Increasing evidence suggests that a recruitment of CRF/urocortin 
mechanisms is more prominent in individuals with increased 
sensitivity to and/or vulnerability for alcohol-induced effects 
(5). After repeated and chronic exposure to alcohol, rats present 
hyperactive extra-hypothalamic CRF activity, as indicated by 
increases in CRF immunoreactivity and/or increases in mRNA 
for CRF and its receptors in amygdala nuclei and the BNST (18, 
182, 183). Consistently, increased alcohol seeking and intake can 
be attenuated after the administration of antagonists to CRF type 
1 receptors (systemically, icv or intra-amygdala), particularly in 
animals with previous alcohol history (5, 18, 81, 106, 109, 110) 
or in high alcohol-consuming mice (76). While blocking CRFR1 
attenuates alcohol drinking, this effect can also be achieved with 
the activation of CRFR2 signaling, suggesting opposite roles for 
CRFR1 and CRFR2 in the modulation of excessive alcohol intake 
[e.g., Ref. (86, 105, 113)]. However, manipulation of CRF receptor 
signaling in different brain regions may reveal differential effects 
and interactions between CRFR1 and CRFR2 [e.g., Ref. (73, 99, 
105, 115)]. Pharmacological studies start to unveil a role for both 
CRF receptors within brain reward pathways, as well as CRF-BP, 
as critical modulators of escalated alcohol drinking [e.g., Ref. 
(74, 84, 89, 115)]. Furthermore, the finding that different CRF 
mechanisms and pathways may be engaged during escalated 
drinking or alcohol withdrawal-related anxiety (99) gives rise 
to an intriguing path for further investigation. Moreover, CRF/
urocortin signaling is also recruited during other alcohol-related 
effects, including alcohol-induced behavioral sensitization, 
alcohol-escalated aggression, and alcohol withdrawal-related 
anxiety. Determination of specific mechanisms for the engage-
ment of CRF, urocortins, CRF-BP, and CRF receptors, after acute 
and chronic alcohol exposure still remain to be clarified. While 
effects of alcohol on the HPA axis, the amygdala, and other 
stress-related structures have been more widely characterized, 
promising contributions of CRF/urocortin signaling in brain 
reward pathways and other structures are starting to emerge. 
Finally, there is hope that new molecules targeting components 
of the CRF/urocortin system will be made available for testing in 
preclinical experimental settings and advancing to clinical trials, 
providing helpful therapeutic tools for the treatment of AUDs.
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